Skip to content

Ground-breaking Alzheimers blood test

At the European Academy of Neurology Congress in Helsinki, researchers unveiled a groundbreaking blood test that could revolutionize Alzheimer’s disease management by identifying patients with mild cognitive impairment (MCI) likely to progress rapidly to severe…… Ground-breaking Alzheimers blood test...

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Donanemab and Lecanemab rejected for the NHS

Two innovative Alzheimer’s drugs, donanemab and lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending independent living, by…… Donanemab and Lecanemab rejected for the NHS...

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here